Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BLCO logo BLCO
Upturn stock ratingUpturn stock rating
BLCO logo

Bausch + Lomb Corp (BLCO)

Upturn stock ratingUpturn stock rating
$14.55
Last Close (24-hour delay)
Profit since last BUY8.18%
upturn advisory
Consider higher Upturn Star rating
BUY since 42 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: BLCO (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

15 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $15.14

1 Year Target Price $15.14

Analysts Price Target For last 52 week
$15.14 Target price
52w Low $10.45
Current$14.55
52w High $21.69

Analysis of Past Performance

Type Stock
Historic Profit -26.32%
Avg. Invested days 37
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 5.15B USD
Price to earnings Ratio -
1Y Target Price 15.14
Price to earnings Ratio -
1Y Target Price 15.14
Volume (30-day avg) 15
Beta 0.62
52 Weeks Range 10.45 - 21.69
Updated Date 08/29/2025
52 Weeks Range 10.45 - 21.69
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.78

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-07-30
When -
Estimate 0.06
Actual 0.07

Profitability

Profit Margin -5.58%
Operating Margin (TTM) 0.86%

Management Effectiveness

Return on Assets (TTM) 0.47%
Return on Equity (TTM) -4.02%

Valuation

Trailing PE -
Forward PE 21.98
Enterprise Value 9845917911
Price to Sales(TTM) 1.05
Enterprise Value 9845917911
Price to Sales(TTM) 1.05
Enterprise Value to Revenue 2.01
Enterprise Value to EBITDA 21.69
Shares Outstanding 353865984
Shares Floating 42131261
Shares Outstanding 353865984
Shares Floating 42131261
Percent Insiders 88.07
Percent Institutions 11.29

ai summary icon Upturn AI SWOT

Bausch + Lomb Corp

stock logo

Company Overview

overview logo History and Background

Bausch & Lomb was founded in 1853 in Rochester, New York, by John Jacob Bausch and Henry Lomb. Initially a small optical goods store, it grew to become a global leader in eye health products, experiencing significant milestones in lens development, surgical technologies, and consumer eye care. In 2013, it was acquired by Valeant Pharmaceuticals. In 2022, Bausch + Lomb became an independent publicly traded company again.

business area logo Core Business Areas

  • Vision Care: Contact lenses (daily disposables, reusable, and specialty lenses) and lens care products (solutions and rewetting drops).
  • Ophthalmic Pharmaceuticals: Prescription medications for various eye conditions including glaucoma, dry eye, and eye infections.
  • Surgical: Surgical instruments, equipment, and consumables for cataract, refractive, and vitreoretinal surgery.

leadership logo Leadership and Structure

Brent Saunders is the Chairman and CEO. The organizational structure is designed around the three core business areas, with functional departments supporting each segment.

Top Products and Market Share

overview logo Key Offerings

  • ULTRA Contact Lenses: Monthly replacement contact lenses for astigmatism and presbyopia. Estimated market share in the monthly lens segment is approximately 10%. Competitors include Alcon (AIR OPTIX), CooperVision (Biofinity), and Johnson & Johnson (Acuvue).
  • Biotrue ONEday: Daily disposable contact lenses made with a bio-inspired material. Market share is approximately 8% in the daily disposable segment. Competitors include Alcon (DAILIES), CooperVision (MyDay), and Johnson & Johnson (Acuvue).
  • Lotemax SM: A corticosteroid ophthalmic suspension used to treat inflammation and pain following ocular surgery. While specific revenue figures are not publicly available, Lotemax SM holds a significant portion of the prescription steroid market. Competitors include Alcon (Lotemax Gel).
  • Storz Ophthalmic Instruments: Surgical instrumentation for ophthalmic procedures. They are a leading supplier of surgical products and instruments. Competitors are Alcon, Johnson & Johnson.

Market Dynamics

industry overview logo Industry Overview

The eye health industry is growing, driven by an aging population, increased prevalence of vision problems (e.g., myopia, presbyopia), and technological advancements in eye care products and surgical procedures.

Positioning

Bausch + Lomb is a well-established player in the eye health market, with a broad portfolio of products across vision care, ophthalmic pharmaceuticals, and surgical. Its competitive advantage lies in its strong brand recognition, global presence, and diverse product offering.

Total Addressable Market (TAM)

The global eye care market is projected to reach approximately $200 billion by 2028. Bausch + Lomb is positioned to capture a significant share of this market through its diverse product portfolio and global reach.

Upturn SWOT Analysis

Strengths

  • Strong brand recognition
  • Global distribution network
  • Diverse product portfolio
  • Established relationships with eye care professionals
  • Innovation in product development

Weaknesses

  • High debt levels (related to its time under Valeant)
  • Exposure to generic competition for pharmaceutical products
  • Slower growth compared to some competitors in specific segments

Opportunities

  • Expanding into emerging markets
  • Developing new products and technologies
  • Acquiring complementary businesses
  • Increasing focus on digital marketing and e-commerce
  • Capitalizing on increasing demand for premium eye care products

Threats

  • Intense competition from other eye care companies
  • Pricing pressure from managed care organizations
  • Changes in regulations
  • Economic downturns
  • Product recalls

Competitors and Market Share

competitor logo Key Competitors

  • ALC
  • COO
  • JNJ

Competitive Landscape

Bausch + Lomb competes with several large and well-established companies. Its advantages include a broad product portfolio and global presence. Disadvantages include high debt levels and slower growth in some segments compared to its peers. They are focused on innovation to maintain a strong presence within the industry.

Major Acquisitions

Acquired Company Name

  • Year: 2024
  • Acquisition Price (USD millions): 125
  • Strategic Rationale: To expand their current eye health segment to the Chinese market and increase company revenue.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been steady, driven by new product launches and geographic expansion.

Future Projections: Analysts project revenue growth of 4-6% per year over the next 3-5 years, driven by continued demand for eye care products and surgical procedures.

Recent Initiatives: Recent initiatives include expanding its presence in China, launching new contact lens products, and investing in research and development.

Summary

Bausch + Lomb is a strong global player in the eye health market with a diverse portfolio and established brand. Its high debt and competitive environment present challenges. Its strengths in branding, global distribution, and product innovation drive growth. They need to focus on debt reduction and leveraging market opportunities to enhance their competitive positioning.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Analyst reports
  • Industry publications
  • Market research reports

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Market data and analyst estimates are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Bausch + Lomb Corp

Exchange NYSE
Headquaters Vaughan, ON, Canada
IPO Launch date 2022-05-06
CEO & Chairman Mr. Brenton L. Saunders J.D.
Sector Healthcare
Industry Medical Instruments & Supplies
Full time employees 13500
Full time employees 13500

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.